BIOTON S.A. (WSE: BIO)

Market Cap	291.51M
Revenue (ttm)	186.32M
Net Income (ttm)	-6.85M
Shares Out	85.86M
EPS (ttm)	-0.08
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,821
Open	3.345
Previous Close	3.345
Day's Range	3.330 - 3.400
52-Week Range	3.300 - 3.900
Beta	0.11
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 31, 2024

About BIOTON

BIOTON S.A., a biotechnology company, develops, manufactures, markets, and sells pharmaceutical ingredient and medicinal products in Poland and internationally. The company offers recombinant human insulin; oral diabetic drugs; strips for measuring sugar in blood, as well as Gensulin N, Gensulin R, and Gensulin M30; GensuPen 2, an automatic injection system; and GensuCare glucometer, a diabetes monitoring technology, as well as needles. BIOTON S.A. was founded in 1989 and is based in Ozarów Mazowiecki, Poland.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1989
• Employees: 357
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: BIO

Financial Performance

In 2023, BIOTON's revenue was 181.64 million, a decrease of -22.10% compared to the previous year's 233.16 million. Earnings were 2.28 million, an increase of 60.10%.